The FDA as given marketing approval to AstraZenica and Brystol Myers Squibb for their new combination product Kombiglyze XR. Kombiglyze XR is a once daily dose of extended-release metformin and saxaglyptin. Saxaglyptin was previously approved by itself as Onglyza. Saxaglyptin is a member of the new class of anti-diabetic drugs called dipeptidyl peptidase-4 inhibitors, of which Merck’s Januvia/Janumet may be a more familiar member. The drug will compete in the already crowded but important marketplace of oral therapies for type-2 diabetes. Both of the DPP-4 inhibitors and their metformin combinations are top-tier and require prior authorization on popular health plans such as Priority Health and Blue Cross/Blue Shield of Michigan.
Monthly Archive for November, 2010
Looking Beyond LDL-C: The Importance Of Lipid Management
Presented by Dr. Jesse Duranceau, D.O.
Promed Internal Medicine
Portage, Michigan
Thursday December 2nd 2010
6:30PM Refreshments
7:00PM Dinner and Speaker
CEU Pending.
RSVP to William Urfer (616)381-2256 or william@swmpa.org by November 29.
Webster’s Prime Steakhouse
inside the Raddison
100 West Michigan Avenue
Kalamazoo, MI
(Parking will be validated)
View Larger Map
Graciously sponsored by Eric Glover And Erin Rich of Abbott Laboratories